
TEM Stock Forecast & Price Target
TEM Analyst Ratings
Bulls say
Tempus AI is a promising technology company with a positive outlook due to their recent acquisition of PSNL, expected growth in commercialization and a target price upgrade to $76, and successful developments, such as FDA approval for a tumor testing product. There is also potential for further growth through their personalized neoantigen therapy and partnerships in manufacturing personalized cancer vaccines. However, risks include achieving projected earnings, competition, and potential financial losses and volatility.
Bears say
Tempus AI is currently trading at a high multiple and has a high price target, but with increasing competition in the healthcare technology industry and the potential limitations around Intismeran's CDx designation, there are concerns about the company's future revenue growth. Additionally, while Tempus has multiple potential revenue streams, including partnerships with Merck and Moderna, these opportunities are still in the early stages and may not generate significant revenue in the near term. Finally, while yesterday's positive Phase 3 readout for personalized neoantigen therapy is a positive development, it may take some time for it to translate into meaningful financial impact for the company.
This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.
TEM Analyst Forecast & Price Prediction
Start investing in TEM
Order type
Buy in
Order amount
Est. shares
0 shares